Prihlásiť sa Zaregistrujte sa zadarmo

Príjmy spoločnosti Neovacs S.A

Aká je hodnota metriky Príjmy spoločnosti Neovacs S.A?

Hodnota metriky Príjmy spoločnosti Neovacs S.A. je -€5.49

Aká je definícia metriky Príjmy?

Výsledok príjmov pre kmeňových akcionárov (Income) sa rovná celkovému príjmu mínus vyplatené prioritné dividendy.

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

Príjmy spoločností v sektore Health Care sektor na EURONEXT v porovnaní so spoločnosťou Neovacs S.A

Čomu sa venuje spoločnosť Neovacs S.A?

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Firmy s metrikou príjmy podobnou spoločnosti Neovacs S.A